ISARIC - Coronavirus Clinical Characterisation Consortium (ISARIC-4C)

Key facts

Disease
COVID-19
Start & end year
2020
2021
Known Financial Commitments (USD)
$98,958.45
Funder
UK Research and Innovation (UKRI)
Principal Investigator
Pending
Research Location
United Kingdom
Lead Research Institution
University of Edinburgh
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
Data Management and Data Sharing
Study Subject
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

This award is being made in support of urgent research costs to enable sampling amongst UK COVID-19 cases. This is essential in developing diagnostics, therapeutics (monoclonal antibodies) and understanding the pathogen and the natural history of the disease, as well as developing rapid prognostic tools. This funding support will ensure samples are distributed safely to researchers. Research could change the course of the rapidly spreading outbreak.

Publicationslinked via Europe PMC

Last Updated:3 days ago

View all publications at Europe PMC

Evaluation of pragmatic oxygenation measurement as a proxy for Covid-19 severity.

CAGE sequencing reveals CFTR-dependent dysregulation of type I IFN signaling in activated cystic fibrosis macrophages.

Patient emergency health-care use before hospital admission for COVID-19 and long-term outcomes in Scotland: a national cohort study.

Neurological manifestations of COVID-19 in adults and children.

Adeno-associated virus 2 infection in children with non-A-E hepatitis.

Authors
Ho A, Orton R, Tayler R, Asamaphan P, Herder V, Davis C, Tong L, Smollett K, Manali M, Allan J, Rawlik K, McDonald SE, Vink E, Pollock L, Gannon L, Evans C, McMenamin J, Roy K, Marsh K, Divala T, Holden MTG, Lockhart M, Yirrell D, Currie S, O'Leary M, Henderson D, Shepherd SJ, Jackson C, Gunson R, MacLean A, McInnes N, Bradley-Stewart A, Battle R, Hollenbach JA, Henderson P, Odam M, Chikowore P, Oosthuyzen W, Chand M, Hamilton MS, Estrada-Rivadeneyra D, Levin M, Avramidis N, Pairo-Castineira E, Vitart V, Wilkie C, DIAMONDS Consortium, ISARIC4C Investigators, Palmarini M, Ray S, Robertson DL, da Silva Filipe A, Willett BJ, Breuer J, Semple MG, Turner D, Baillie JK, Thomson EC.
Publish Year
2023
Journal
Nature
DOI
10.1038/s41586-023-05948-2

View at Europe PMC

Variation in ERAP2 has opposing effects on severe respiratory infection and autoimmune disease.

Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study.

Comorbidities, multimorbidity and COVID-19.

Estimating distribution of length of stay in a multi-state model conditional on the pathway, with an application to patients hospitalised with Covid-19.